Skip to main content

Advertisement

SpringerLink
Log in

Chronic lung allograft dysfunction after lung transplantation: the moving target

  • Current Topics Review Article
  • Published:
General Thoracic and Cardiovascular Surgery Aims and scope Submit manuscript

Abstract

Chronic lung allograft dysfunction is a major challenge in long-term management of lung transplant recipients. Both alloimmune-dependent factors (rejection) and alloimmune-independent factors contribute to the development of chronic lung allograft dysfunction. Thus, use of the term “chronic rejection” tends to be intentionally avoided among specialists in the field, although “chronic rejection” is still an acceptable lay word understood by many patients. Several different phenotypes have been identified in chronic lung allograft dysfunction, including restrictive allograft syndrome, neutrophilic reversible allograft dysfunction, and fibrous bronchiolitis obliterans syndrome. Restrictive allograft syndrome is characterized by restrictive physiology and peripheral foci of inflammation and fibrosis, which contrasts the obstructive physiology and pathological foci in small airways in conventional bronchiolitis obliterans syndrome. Among patients with bronchiolitis obliterans syndrome, there is a subpopulation that responds relatively well to azithromycin. Because these patients show airway neutrophilia, this subtype of chronic lung allograft dysfunction was named neutrophilic reversible allograft dysfunction. Conversely, patients with bronchiolitis obliterans syndrome unresponsive to azithromycin show airway fibrosis with less inflammation (fibrous bronchiolitis obliterans syndrome). In general, restrictive allograft syndrome shows poorer survival than does bronchiolitis obliterans syndrome, and early-onset bronchiolitis obliterans syndrome (within 2 years) shows a worse prognosis than does late-onset bronchiolitis obliterans syndrome. Until preventive and therapeutic options are refined, chronic lung allograft dysfunction will remain a major life-limiting factor. It has significant psychological, physical, social, and economic impacts. Early introduction of palliative care is another important strategy to improve patients’ quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth Adult Lung and Heart-Lung Transplant Report—2011. J Heart Lung Transplant. 2011;30:1104–22.

    Article  PubMed  Google Scholar 

  2. Sato M, Keshavjee S. Bronchiolitis obliterans syndrome: alloimmune-dependent and -independent injury with aberrant tissue remodeling. Semin Thorac Cardiovasc Surg. 2008;20:173–82.

    Article  PubMed  Google Scholar 

  3. Pakhale SS, Hadjiliadis D, Howell DN, Palmer SM, Gutierrez C, Waddell TK, et al. Upper lobe fibrosis: a novel manifestation of chronic allograft dysfunction in lung transplantation. J Heart Lung Transplant. 2005;24:1260–8.

    Article  PubMed  Google Scholar 

  4. Woodrow JP, Shlobin OA, Barnett SD, Burton N, Nathan SD. Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant. 2010;29:1159–64.

    Article  PubMed  Google Scholar 

  5. Sato M, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, et al. Restrictive allograft syndrome (RAS): a novel form of chronic allograft dysfunction after lung transplantation. J Heart Lung Transplant. 2011;30:735–42.

    Article  PubMed  Google Scholar 

  6. Reitz BA, Wallwork JL, Hunt SA, Pennock JL, Billingham ME, Oyer PE, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med. 1982;306:557–64.

    Article  PubMed  CAS  Google Scholar 

  7. Toroto Lung Transplant Group. Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med. 1986;314:1140–5.

    Article  Google Scholar 

  8. Burke CM, Theodore J, Dawkins KD, Yousem SA, Blank N, Billingham ME, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest. 1984;86:824–9.

    Article  PubMed  CAS  Google Scholar 

  9. Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am J Respir Crit Care Med. 2003;168:1277–92.

    Article  PubMed  Google Scholar 

  10. Cooper JD, Billingham M, Egan T, Hertz MI, Higenbottam T, Lynch J, International Society for Heart and Lung Transplantation, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant. 1993;12:713–6.

    PubMed  CAS  Google Scholar 

  11. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21:297–310.

    Article  PubMed  Google Scholar 

  12. Davis RD Jr, Lau CL, Eubanks S, Messier RH, Hadjiliadis D, Steele MP, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg. 2003;125:533–42.

    Article  PubMed  Google Scholar 

  13. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med. 2010;181:1391–6.

    Article  PubMed  Google Scholar 

  14. Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21:559–66.

    Article  PubMed  Google Scholar 

  15. Botha P, Archer L, Anderson RL, Lordan J, Dark JH, Corris PA, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation. 2008;85:771–4.

    Article  PubMed  Google Scholar 

  16. Palmer SM, Burch LH, Trindade AJ, Davis RD, Herczyk WF, Reinsmoen NL, et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med. 2005;171:780–5.

    Article  PubMed  Google Scholar 

  17. Burlingham WJ, Love RB, Jankowska-Gan E, Haynes LD, Xu Q, Bobadilla JL, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. 2007;117:3498–506.

    Article  PubMed  CAS  Google Scholar 

  18. Goers TA, Ramachandran S, Aloush A, Trulock E, Patterson GA, Mohanakumar T. De novo production of K-{alpha}1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol. 2008;180:4487–94.

    PubMed  CAS  Google Scholar 

  19. Sato M, Liu M, Anraku M, Ogura T, D’Cruz G, Alman BA, et al. Allograft airway fibrosis in the pulmonary milieu: a disorder of tissue remodeling. Am J Transplant. 2008;8:517–28.

    Article  PubMed  CAS  Google Scholar 

  20. Vanaudenaerde BM, Meyts I, Vos R, Geudens N, De Wever W, Verbeken EK, et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J. 2008;32:832–43.

    Article  PubMed  CAS  Google Scholar 

  21. Sato M, Hwang DM, Ohmori-Matsuda K, Chaparro C, Waddell TK, Singer LG, et al. Revisiting the pathologic finding of diffuse alveolar damage after lung transplantation. J Heart Lung Transplant. 2012;31:354–63.

    Article  PubMed  Google Scholar 

  22. Verleden GM, Vos R, Verleden SE, De Wever W, De Vleeschauwer SI, Willems-Widyastuti A, et al. Survival determinants in lung transplant patients with chronic allograft dysfunction. Transplantation. 2011;92:703–8.

    Article  PubMed  Google Scholar 

  23. Martinu T, Howell DN, Davis RD, Steele MP, Palmer SM. Pathologic correlates of bronchiolitis obliterans syndrome in pulmonary retransplant recipients. Chest. 2006;129:1016–23.

    Article  PubMed  Google Scholar 

  24. de Jong PA, Vos R, Verleden GM, Vanaudenaerde BM, Verschakelen JA. Thin-section computed tomography findings before and after azithromycin treatment of neutrophilic reversible lung allograft dysfunction. Eur Radiol. 2011;21:2466–74.

    Article  PubMed  Google Scholar 

  25. Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer MR. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant. 2005;24:1440–3.

    Article  PubMed  Google Scholar 

  26. Yates B, Murphy DM, Forrest IA, Ward C, Rutherford RM, Fisher AJ, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2005;172:772–5.

    Article  PubMed  Google Scholar 

  27. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008;85:36–41.

    Article  PubMed  CAS  Google Scholar 

  28. Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med. 2008;177:1033–40.

    Article  PubMed  Google Scholar 

  29. Vos R, Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Van Raemdonck DE, et al. Bronchoalveolar lavage neutrophilia in acute lung allograft rejection and lymphocytic bronchiolitis. J Heart Lung Transplant. 2010;29:1259–69.

    Article  PubMed  Google Scholar 

  30. Jackson CH, Sharples LD, McNeil K, Stewart S, Wallwork J. Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities? J Heart Lung Transplant. 2002;21:658–66.

    Article  PubMed  Google Scholar 

  31. Finlen Copeland CA, Snyder LD, Zaas DW, Turbyfill WJ, Davis WA, Palmer SM. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med. 2010;182:784–9.

    Article  PubMed  Google Scholar 

  32. Brugiere O, Pessione F, Thabut G, Mal H, Jebrak G, Leseche G, et al. Bronchiolitis obliterans syndrome after single-lung transplantation: impact of time to onset on functional pattern and survival. Chest. 2002;121:1883–9.

    Article  PubMed  Google Scholar 

  33. Lama VN, Murray S, Lonigro RJ, Toews GB, Chang A, Lau C, et al. Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients. Am J Respir Crit Care Med. 2007;175:1192–8.

    Article  PubMed  Google Scholar 

  34. Sato M, Ohmori-Matsuda K, Singer LG, Keshavjee S. Risk of Patient Death after CLAD Onset: BOS and RAS as time-dependent covariates in a cox model (abstract). J Heart Lung Transplant. 2012;31:S123.

    Article  Google Scholar 

  35. Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J. 2003;22:1007–18.

    Article  PubMed  CAS  Google Scholar 

  36. Jaramillo A, Fernandez FG, Kuo EY, Trulock EP, Patterson GA, Mohanakumar T. Immune mechanisms in the pathogenesis of bronchiolitis obliterans syndrome after lung transplantation. Pediatr Transplant. 2005;9:84–93.

    Article  PubMed  Google Scholar 

  37. Todd JL, Palmer SM. Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. Chest. 2011;140:502–8.

    Article  PubMed  Google Scholar 

  38. Douglas MR, Morrison KE, Salmon M, Buckley CD. Why does inflammation persist: a dominant role for the stromal microenvironment? Expert Rev Mol Med. 2002;2002:1–18.

    Google Scholar 

  39. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol. 2006;6:205–17.

    Article  PubMed  CAS  Google Scholar 

  40. Manzo A, Bugatti S, Caporali R, Prevo R, Jackson DG, Uguccioni M, et al. CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis. Am J Pathol. 2007;171:1549–62.

    Article  PubMed  CAS  Google Scholar 

  41. Thaunat O, Patey N, Morelon E, Michel JB, Nicoletti A. Lymphoid neogenesis in chronic rejection: the murderer is in the house. Curr Opin Immunol. 2006;18:576–9.

    Article  PubMed  CAS  Google Scholar 

  42. Sato M, Hirayama S, Hwang DM, Lara-Guerra H, Wagnetz D, Waddell TK, et al. The role of intrapulmonary de novo lymphoid tissue in obliterative bronchiolitis after lung transplantation. J Immunol. 2009;182:7307–16.

    Article  PubMed  CAS  Google Scholar 

  43. Sato M, Hirayama S, Matsuda Y, Wagnetz D, Hwang D, Guan Z, et al. Stromal activation and formation of lymphoid-like stroma in chronic lung allograft dysfunction. Transplantation. 2011;91:1398–405.

    Article  PubMed  CAS  Google Scholar 

  44. Fouser LA, Wright JF, Dunussi-Joannopoulos K, Collins M. Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev. 2008;226:87–102.

    Article  PubMed  CAS  Google Scholar 

  45. Deteix C, Attuil-Audenis V, Duthey A, Patey N, McGregor B, Dubois V, et al. Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J Immunol. 2010;184(9):5344–51.

    Article  PubMed  CAS  Google Scholar 

  46. McNeil K, Glanville AR, Wahlers T, Knoop C, Speich R, Mamelok RD, et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation. 2006;81:998–1003.

    Article  PubMed  CAS  Google Scholar 

  47. Iacono AT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seiler DA, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006;354:141–50.

    Article  PubMed  Google Scholar 

  48. Cantu E 3rd, Appel JZ 3rd, Hartwig MG, Woreta H, Green C, Messier R, et al. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg. 2004;78:1142–51.

    Article  PubMed  Google Scholar 

  49. Hartwig MG, Anderson DJ, Onaitis MW, Reddy S, Snyder LD, Lin SS, et al. Fundoplication after lung transplantation prevents the allograft dysfunction associated with reflux. Ann Thorac Surg. 2011;92:462–8.

    Google Scholar 

  50. Vos R, Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Van Raemdonck DE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J. 2011;37:164–72.

    Article  PubMed  CAS  Google Scholar 

  51. Lama VN, Murray S, Mumford JA, Flaherty KR, Chang A, Toews GB, et al. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients. Am J Respir Crit Care Med. 2005;172:379–83.

    Article  PubMed  Google Scholar 

  52. Palmer SM, Davis RD, Hadjiliadis D, Hertz MI, Howell DN, Ward FE, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation. 2002;74:799–804.

    Article  PubMed  CAS  Google Scholar 

  53. Sundaresan S, Mohanakumar T, Smith MA, Trulock EP, Lynch J, Phelan D, et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation. 1998;65:648–53.

    Article  PubMed  CAS  Google Scholar 

  54. Hachem RR, Yusen RD, Meyers BF, Aloush AA, Mohanakumar T, Patterson GA, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant. 2010;29:973–80.

    Article  PubMed  Google Scholar 

  55. Stuckey LJ, Kamoun M, Chan KM. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction. Ann Pharmacother. 2012;46:e2.

    Article  PubMed  Google Scholar 

  56. Sato M, Waddell KT, Hwang DM, Chaparro C, Singer LG, Hutcheon MA, et al. The role of open lung biopsy in lung-transplant recipients: does the establishment of restrictive allograft syndrome (RAS) change practice? (abstract) J Heart Lung Transplant. 2011;30:S51.

    Google Scholar 

  57. Strueber M, Fischer S, Gottlieb J, Simon AR, Goerler H, Gohrbandt B, et al. Long-term outcome after pulmonary retransplantation. J Thorac Cardiovasc Surg. 2006;132:407–12.

    Article  PubMed  Google Scholar 

  58. Song MK, De Vito Dabbs A, Studer SM, Zangle SE. Course of illness after the onset of chronic rejection in lung transplant recipients. Am J Crit Care. 2008;17:246–53.

    PubMed  Google Scholar 

  59. Stilley CS, Dew MA, Stukas AA, Switzer GE, Manzetti JD, Keenan RJ, et al. Psychological symptom levels and their correlates in lung and heart-lung transplant recipients. Psychosomatics. 1999;40:503–9.

    Article  PubMed  CAS  Google Scholar 

  60. Kunsebeck HW, Kugler C, Fischer S, Simon AR, Gottlieb J, Welte T, et al. Quality of life and bronchiolitis obliterans syndrome in patients after lung transplantation. Prog Transplant. 2007;17:136–41.

    PubMed  Google Scholar 

  61. Ullrich G, Jansch H, Schmidt S, Struber M, Niedermeyer J. The experience of the support person involved in a lung transplant programme: results of a pilot study. Eur J Med Res. 2004;9:555–652.

    PubMed  CAS  Google Scholar 

  62. Kelley AS, Meier DE. Palliative care—a shifting paradigm. N Engl J Med. 2010;363:781–2.

    Article  PubMed  CAS  Google Scholar 

  63. Higginson IJ, Finlay IG, Goodwin DM, Hood K, Edwards AG, Cook A, et al. Is there evidence that palliative care teams alter end-of-life experiences of patients and their caregivers? J Pain Symptom Manage. 2003;25:150–68.

    Article  PubMed  Google Scholar 

  64. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733–42.

    Article  PubMed  CAS  Google Scholar 

  65. Song MK, De Vito Dabbs A, Studer SM, Arnold RM. Palliative care referrals after lung transplantation in major transplant centers in the United States. Crit Care Med. 2009;37:1288–92.

    Article  PubMed  Google Scholar 

  66. Rodriguez KL, Barnato AE, Arnold RM. Perceptions and utilization of palliative care services in acute care hospitals. J Palliat Med. 2007;10:99–110.

    Article  PubMed  Google Scholar 

  67. Lanken PN, Terry PB, Delisser HM, Fahy BF, Hansen-Flaschen J, Heffner JE, et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med. 2008;177:912–27.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, Kyoto University Hospital, 54-Kawara-chyo, Sakyo-ku, Kyoto, Japan

    Masaaki Sato

  2. Latner Thoracic Surgery Research Laboratories, University of Toronto, Toronto, Canada

    Masaaki Sato

Authors
  1. Masaaki Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaaki Sato.

Additional information

The review was submitted at the invitation of the editorial committee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sato, M. Chronic lung allograft dysfunction after lung transplantation: the moving target. Gen Thorac Cardiovasc Surg 61, 67–78 (2013). https://doi.org/10.1007/s11748-012-0167-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11748-012-0167-3

Keywords

Search

Navigation